Format

Send to

Choose Destination
Expert Rev Cardiovasc Ther. 2015 Feb;13(2):121-3. doi: 10.1586/14779072.2015.1000305. Epub 2015 Jan 5.

Percutaneous closure of patent foramen ovale: safe and effective but underutilized.

Author information

1
University Heart Center Zurich, Zurich, Switzerland.

Abstract

With three recently published randomized trials on patent foramen ovale (PFO) closure, the concept of PFO closure to reduce recurrent strokes has been proven; however, PFO closure is currently only considered for secondary prevention. Given the potential devastating consequences of a PFO-related event, we advocate screening for and closure of a PFO for primary prevention in high-risk populations. Such populations include patients who are suffering from a disease that is associated with PFO (e.g., migraine) or patients with high-risk hobbies/professions (e.g., weight-lifters, frequent-flyers, and deep sea divers). Looking at young people with a remaining average life expectancy of 50 years, we have to close 2.4 PFOs to prevent one stroke. This should support a more proactive attitude toward PFO screening and closure.

KEYWORDS:

migraine; patent foramen ovale; percutaneous PFO closure; prevention; stroke

PMID:
25556896
DOI:
10.1586/14779072.2015.1000305
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center